|
Report Date : |
16.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
SEVEN STAR PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
75, Fwu An St., Tucheng Dist., New |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
26.10.1962 |
|
|
|
|
Com. Reg. No.: |
33001851 |
|
|
|
|
Legal Form : |
Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and sales of BPC(bulk pharmaceutical chemicals) |
|
|
|
|
No. of Employees : |
About 50 employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Taiwan |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company Name: |
|
|
Supplied Name: |
|
|
Trading Address: |
75, Fwu An St., Tucheng Dist., New Taipei
City 236, Taiwan (R.O.C.) |
|
Supplied Address: |
|
|
Telephone Number: |
|
|
Fax Number: |
|
|
E-mail: |
|
|
Website: |
Notes: Subject’s exact name and address are as above.
|
Credit Opinion: |
|
Registered Name: |
Seven Star Pharmaceutical Co., Ltd. |
|
Registered Address: |
75, Fwu An St., Tucheng Dist., New Taipei City 236, Taiwan (R.O.C.) |
|
Date of Foundation: |
|
|
Registration Number: |
33001851 |
|
Registry: |
New Taipei City Government |
|
Registered Capital: |
NTD 93,995,220 (USD 3,148,840) (As of 2012.06, 1 NTD = 0.0335 USD) |
|
Paid-up Capital: |
NTD 93,995,220 (USD 3,148,840) |
|
Legal Representatives: |
Yonglong Zeng |
|
Legal Form: |
|
|
Principal Activities: |
Manufacture and sales
of BPC(bulk
pharmaceutical chemicals) |
|
Staff: |
|
|
Listed at Stock
Exchange: |
|
|
Date of Last
Annual Return: |
Subject was incorporated on
|
Name |
Subscription Shares |
|
Yonglong Zeng |
662,912 |
|
Zhongying Wang |
|
|
494,327 |
|
|
Deliang Shen |
6,552 |
|
Liming Zheng |
519,322 |
|
Yongcong Zhou |
529,506 |
|
Qirui Li |
412,258 |
The information above is that of subject’s major shareholders.
Core
Management
|
1 |
|
|
Name |
Yonglong Zeng |
|
Position |
Board Chairman |
|
2 |
|
|
Name |
Zhongying Wang |
|
Position |
Supervisor |
|
3 |
|
|
Name |
Deliang Shen |
|
Position |
Director |
|
4 |
|
|
Name |
Liming Zheng |
|
Position |
Director |
|
5 |
|
|
Name |
Yongcong Zhou |
|
Position |
Director |
|
6 |
|
|
Name |
Qirui Li |
|
Position |
Director |
Personnel
Structure
|
Total Employees |
About 50 employees |
Offices
& Factories
|
|
Headquarters |
|
Add |
75, Fwu An St., Tucheng Dist., New Taipei City 236, Taiwan (R.O.C.) |
Production
Information
l
Subject is engaged in manufacture of BPC(bulk
pharmaceutical chemicals)
l
Subject has passed the certification of ISO 9002
Purchase
Information
l
The registered activities of subject:
|
-- |
Manufacture, processing and sales of pharmaceutical |
|
-- |
Agent and sales of domestic and overseas pharmaceutical |
|
-- |
Combining,
manufacture and sales of relevant pharmaceutical
raw materials. |
|
-- |
Manufacture and sales of ancillary industrial
materials of pharmaceutical raw
materials. |
|
-- |
Manufacture and
sales of NaAC, ferrisulphas and other food additives |
l
Subject purchases raw materials both at home and
abroad and it is introduced that subject purchases from Asia and Europe, etc
l
The subject is mainly engaged in sales of BPC (bulk
pharmaceutical chemicals)
including Ampicillin, Amoxcycillin, Dicloxacillin, Erythromycin, Cloxacillin
and Roxithromycin, etc
l
Subject’s products are both sold in domestic and
overseas market and it exports to USA, Germany, Japan, Mexico, South America,
Middle East, South East Asia, New Zealand and Australia, etc
l
Subject’s major customers are domestic and overseas
pharmaceutical factories, etc
Import and export
right:
|
Import right |
Yes |
|
Export right |
Yes |
Purchase
Domestic Purchase
|
Payment Terms |
Proportion |
|
|
Raw materials, etc |
COD, CBD, etc |
100% |
Foreign Purchase
|
Payment Terms |
Proportion |
|
|
Raw materials, etc |
CBD, etc |
100% |
Sales
Domestic Markets
|
Sales Terms |
Proportion |
|
|
CBD, etc |
100% |
Export
|
Sales Terms |
Proportion |
|
|
CBD, etc |
100% |
Subject has no obligations to disclose its financial statements to the
third party according to the relevant policy in Taiwan and the only source from
which we can obtain the information is the subject itself.
Subject’s relevant staff Ms. Wang declined to disclose its financials
citing the grounds of company’s confidentiality; from other source we can not
obtain the relevant information, either.
Subject declined
to disclose its bank details and it also declined to confirm the supplies
banker Chang Hwa Commercial Bank Ltd, either.
Mortgage
No chattel
mortgage record of subject has been found within the recent 3 months.
Lawsuit
Up to date of reporting, no existing or latent litigation of the subject has been found.
|
Name |
Ms. Wang |
|
Department |
Sales department |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.76 |
|
UK Pound |
1 |
Rs.86.69 |
|
Euro |
1 |
Rs.70.44 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.